Dr. Matthias Magoola

Dr. Matthias Magoola, was in June 2025 awarded the national “Faces of Science” in Uganda accolade for his outstanding contribution to biotechnology and pharmaceutical innovation in Uganda leads Dei BioPharma Ltd.

Dr. Magoola recently published a scientific paper on RNA-based cancer vaccines in the peer-reviewed journal – and it’s update paper titled; Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update; (https://www.mdpi.com/2072-6694/17/11/1882) offers more solutions advanced by this technology.

Dr. Magoola’s research portfolio covers diseases such as cancer, HIV/AIDS, malaria, tuberculosis, sickle cell disease, diabetes, and Alzheimer’s.

Under his leadership, Dei Biopharma has also filled over 100 patents with the United States Patent and Trademark Office (USPTO) for various therapeutic interventions, including a CAR-T cell immunotherapy for cancer will cost less than $100 per patient, compared to current treatments costing over $500,000.